Cases & Deals

  • Home
  • Practices
  • Puma Biotechnology defends European patent licensed from Wyeth covering Neratinib and Vinorelbine in opposition proceedings

Share

Puma Biotechnology defends European patent licensed from Wyeth covering Neratinib and Vinorelbine in opposition proceedings

September 2015

Clients Puma Biotechnology, Inc.

Jones Day represents Puma Biotechnology, Inc. in European opposition proceedings initiated by Mylan to defend a patent licensed from Wyeth covering Neratinib and Vinorelbine.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.